Posted: April 9, 2010

AuraSense Announces Formation of Advisory Board

(Nanowerk News) AuraSense, a biotechnology company founded to pursue the unique therapeutic potential of engineered nanoparticles, announces the formation of their Advisory Board.
The company is very fortunate to have engaged a set of internationally renowned and highly qualified individuals in its mission to develop nanoparticle therapeutics. The members of the Advisory Board are five distinguished experts in Cancer, Cardiology, Gene Expression and Pharmaceuticals. They will advise AuraSense on furthering its scientific and commercial pursuits within its Gene Regulation, HDL and Intracellular Assay platforms.
AuraSense founder Dr. Chad A. Mirkin noted that: “The Advisory Board represents a world class group of scientists, clinicians, and business leaders who nicely complement the AuraSense team. We are now well-positioned to greatly accelerate our developments targeting oncology, cardiovascular, neurodegenerative, and anti-infective indications, among many others.”
About AuraSense, LLC
AuraSense, LLC is a privately-held biotechnology company founded in February, 2009.
AuraSense's engineered nanoparticles possess unparalleled biocompatibility and versatility as therapeutics and as novel assays within live cells, and they hold great promise for combating the world’s most threatening diseases. The company's constructs overcome one of the most difficult obstacles to gene regulation: safe and effective entry into cells. AuraSense particles exhibit high stability, high binding specificity, and unparalleled transfection efficiency into numerous cell and tissue types. Needing no carriers or transfection agents, they provoke minimal immune response and no known toxicity. AuraSense has also developed nanoparticles that mimic the natural function of HDL ("good" cholesterol). These structures bind cholesterol tightly and have demonstrated activity and minimal toxicity in animal models.
AuraSense’s technology originated in the labs of Professors Chad A. Mirkin and C. Shad Thaxton at the Northwestern University International Institute for Nanotechnology.
Source: Dow Chemical (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: